Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Original investigation

Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects

Authors: Manoj Mathew, Eric Tay, Kenneth Cusi

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Abstract

Background

CVD in obesity and T2DM are associated with endothelial activation, elevated plasma vascular inflammation markers and a prothrombotic state. We examined the contribution of FFA to these abnormalities following a 48-hour physiological increase in plasma FFA to levels of obesity and diabetes in a group of healthy subjects.

Methods

40 non-diabetic subjects (age = 38 ± 3 yr, BMI = 28 ± 1 kg/m2, FPG = 95 ± 1 mg/dl, HbA1c = 5.3 ± 0.1%) were admitted twice and received a 48-hour infusion of normal saline or low-dose lipid. Plasma was drawn for intracellular (ICAM-1) and vascular (VCAM-1) adhesion molecules-1, E-selectin (sE-S), myeloperoxidase (MPO) and total plasminogen inhibitor-1 (tPAI-1). Insulin sensitivity was measured by a hyperglycemic clamp (M/I).

Results

Lipid infusion increased plasma FFA to levels observed in obesity and T2DM and reduced insulin sensitivity by 27% (p = 0.01). Elevated plasma FFA increased plasma markers of endothelial activation ICAM-1 (138 ± 10 vs. 186 ± 25 ng/ml), VCAM-1 (1066 ± 67 vs. 1204 ± 65 ng/ml) and sE-S (20 ± 1 vs. 24 ± 1 ng/ml) between 13-35% and by ≥ 2-fold plasma levels of myeloperoxidase (7.5 ± 0.9 to 15 ± 25 ng/ml), an inflammatory marker of future CVD, and tPAI-1 (9.7 ± 0.6 to 22.5 ± 1.5 ng/ml), an indicator of a prothrombotic state (all p ≤ 0.01). The FFA-induced increase was independent from the degree of adiposity, being of similar magnitude in lean, overweight and obese subjects.

Conclusions

An increase in plasma FFA within the physiological range observed in obesity and T2DM induces markers of endothelial activation, vascular inflammation and thrombosis in healthy subjects. This suggests that even transient (48-hour) and modest increases in plasma FFA may initiate early vascular abnormalities that promote atherosclerosis and CVD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cernuda-Morollon E, Ridley A: Rho GTPases and leukocyte adhesion receptor expression and function in endothelial cells. Circ Res. 2006, 98: 757-767. 10.1161/01.RES.0000210579.35304.d3.CrossRefPubMed Cernuda-Morollon E, Ridley A: Rho GTPases and leukocyte adhesion receptor expression and function in endothelial cells. Circ Res. 2006, 98: 757-767. 10.1161/01.RES.0000210579.35304.d3.CrossRefPubMed
2.
go back to reference Blankenberg S, Barbaux S, L T: Adhesion molecules and atherosclerosis. Atherosclerosis. 2003, 170: 191-203. 10.1016/S0021-9150(03)00097-2.CrossRefPubMed Blankenberg S, Barbaux S, L T: Adhesion molecules and atherosclerosis. Atherosclerosis. 2003, 170: 191-203. 10.1016/S0021-9150(03)00097-2.CrossRefPubMed
3.
go back to reference Collins T, Read M, Neish A, Whitley M, Thanos D, Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF- kappa B and cytokine-inducible enhancers. FASEB J. 1995, 9: 899-909.PubMed Collins T, Read M, Neish A, Whitley M, Thanos D, Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF- kappa B and cytokine-inducible enhancers. FASEB J. 1995, 9: 899-909.PubMed
4.
go back to reference Savoia C, Ernesto L: Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clinical Science. 2007, 112: 375-384. 10.1042/CS20060247.CrossRefPubMed Savoia C, Ernesto L: Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clinical Science. 2007, 112: 375-384. 10.1042/CS20060247.CrossRefPubMed
5.
go back to reference Read MA, Read MA, Whitley MZ, Gupta S, Pierce JW, Best J, Davis RJ, Colins T: Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. The Journal of Biological Chemistry. 1997, 272: 2753-2761. 10.1074/jbc.272.29.18498.CrossRefPubMed Read MA, Read MA, Whitley MZ, Gupta S, Pierce JW, Best J, Davis RJ, Colins T: Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. The Journal of Biological Chemistry. 1997, 272: 2753-2761. 10.1074/jbc.272.29.18498.CrossRefPubMed
6.
go back to reference Yenya H, Jeanne-Marie K, Brian ES, Rosenzweig A, Gimbrone M: E-Selectin-dependent signaling via the mitogen-activated protein kinase pathway in vascular endothelial cells. J Immunol. 2000, 165: 2142-2148.CrossRef Yenya H, Jeanne-Marie K, Brian ES, Rosenzweig A, Gimbrone M: E-Selectin-dependent signaling via the mitogen-activated protein kinase pathway in vascular endothelial cells. J Immunol. 2000, 165: 2142-2148.CrossRef
7.
go back to reference Hu Y, Kiely J, Szente B, Rosenzweig A, Gimbrone MJ: E-selectin-dependent signaling via the mitogen-activated protein kinase pathway in vascular endothelial cells. J Immunol. 2000, 165: 2142-2148.CrossRefPubMed Hu Y, Kiely J, Szente B, Rosenzweig A, Gimbrone MJ: E-selectin-dependent signaling via the mitogen-activated protein kinase pathway in vascular endothelial cells. J Immunol. 2000, 165: 2142-2148.CrossRefPubMed
9.
go back to reference Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. The Lancet. 1998, 351: 88-92. 10.1016/S0140-6736(97)09032-6.CrossRef Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. The Lancet. 1998, 351: 88-92. 10.1016/S0140-6736(97)09032-6.CrossRef
10.
go back to reference Li H, Cybulsky M, Gimbrone M, Libby P: An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arteriosclerosis and Thrombosis. 1993, 13: 197-204.CrossRefPubMed Li H, Cybulsky M, Gimbrone M, Libby P: An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arteriosclerosis and Thrombosis. 1993, 13: 197-204.CrossRefPubMed
11.
go back to reference Deanfield J, Halcox J, Rabelink T: Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007, 115 (10): 1285-1295.PubMed Deanfield J, Halcox J, Rabelink T: Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007, 115 (10): 1285-1295.PubMed
12.
go back to reference Ingelsson E, Hulthe J, Lind L: Inflammatory markers in relation to insulin resistance and the metabolic syndrome. European Journal of Clinical Investigation. 2008, 38: 502-509. 10.1111/j.1365-2362.2008.01962.x.CrossRefPubMed Ingelsson E, Hulthe J, Lind L: Inflammatory markers in relation to insulin resistance and the metabolic syndrome. European Journal of Clinical Investigation. 2008, 38: 502-509. 10.1111/j.1365-2362.2008.01962.x.CrossRefPubMed
13.
go back to reference Soro-Paavonen A, Westerbacka J, Ehnholm C, Taskinen M-R: Metabolic syndrome aggravates the increased endothelial activation and low-grade inflammation in subjects with familial low HDL. Annals of Medicine. 2006, 38: 229-238. 10.1080/07853890500526352.CrossRefPubMed Soro-Paavonen A, Westerbacka J, Ehnholm C, Taskinen M-R: Metabolic syndrome aggravates the increased endothelial activation and low-grade inflammation in subjects with familial low HDL. Annals of Medicine. 2006, 38: 229-238. 10.1080/07853890500526352.CrossRefPubMed
14.
go back to reference Miller MA, Cappuccio FP: Cellular adhesion molecules and their relationship with measures of obesity and metabolic syndrome in a multiethnic population. Int J Obes. 2006, 30: 1176-1182. 10.1038/sj.ijo.0803264.CrossRef Miller MA, Cappuccio FP: Cellular adhesion molecules and their relationship with measures of obesity and metabolic syndrome in a multiethnic population. Int J Obes. 2006, 30: 1176-1182. 10.1038/sj.ijo.0803264.CrossRef
15.
go back to reference Hwang S, Ballantyne C, Sharrett AR, Smith L, Davis C, Gotto A, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The atherosclerosis risk in communities (ARIC) study. Circulation. 1997, 96: 4219-4225.CrossRefPubMed Hwang S, Ballantyne C, Sharrett AR, Smith L, Davis C, Gotto A, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The atherosclerosis risk in communities (ARIC) study. Circulation. 1997, 96: 4219-4225.CrossRefPubMed
16.
go back to reference Tardif JC: Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 2006, 113 (25): 2936-10.1161/CIRCULATIONAHA.105.598987.CrossRefPubMed Tardif JC: Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 2006, 113 (25): 2936-10.1161/CIRCULATIONAHA.105.598987.CrossRefPubMed
17.
go back to reference Vaughan D: PAI-1 and atherothrombosis. Journal of Thrombosis and Haemostasis. 2005, 3: 1879-1883. 10.1111/j.1538-7836.2005.01420.x.CrossRefPubMed Vaughan D: PAI-1 and atherothrombosis. Journal of Thrombosis and Haemostasis. 2005, 3: 1879-1883. 10.1111/j.1538-7836.2005.01420.x.CrossRefPubMed
18.
go back to reference McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ: Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia. 1996, 39: 1512-1518. 10.1007/s001250050606.CrossRefPubMed McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ: Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia. 1996, 39: 1512-1518. 10.1007/s001250050606.CrossRefPubMed
19.
go back to reference Viitanen L, Pihlajamäki J, Halonen P, Lehtonen M, Kareinen A, Lehto S: Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease. Atherosclerosis. 2001, 157: 57-64. 10.1016/S0021-9150(00)00705-X.CrossRefPubMed Viitanen L, Pihlajamäki J, Halonen P, Lehtonen M, Kareinen A, Lehto S: Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease. Atherosclerosis. 2001, 157: 57-64. 10.1016/S0021-9150(00)00705-X.CrossRefPubMed
20.
go back to reference Festa A, D'Agostino R, Tracy R, Haffner S: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predictthe development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2002, 51: 1131-1137. 10.2337/diabetes.51.4.1131.CrossRefPubMed Festa A, D'Agostino R, Tracy R, Haffner S: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predictthe development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2002, 51: 1131-1137. 10.2337/diabetes.51.4.1131.CrossRefPubMed
21.
go back to reference Nicholls S, Hazen S: Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005, 25: 1102-1111. 10.1161/01.ATV.0000163262.83456.6d.CrossRefPubMed Nicholls S, Hazen S: Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005, 25: 1102-1111. 10.1161/01.ATV.0000163262.83456.6d.CrossRefPubMed
22.
go back to reference Hazen SL, Heinecke JW: 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. The Journal of Clinical Investigation. 1997, 99: 2075-2081. 10.1172/JCI119379.PubMedCentralCrossRefPubMed Hazen SL, Heinecke JW: 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. The Journal of Clinical Investigation. 1997, 99: 2075-2081. 10.1172/JCI119379.PubMedCentralCrossRefPubMed
23.
go back to reference Daugherty A, Dunn J, Rateri D, Heinecke J: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. The Journal of Clinical Investigation. 1994, 94: 437-444. 10.1172/JCI117342.PubMedCentralCrossRefPubMed Daugherty A, Dunn J, Rateri D, Heinecke J: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. The Journal of Clinical Investigation. 1994, 94: 437-444. 10.1172/JCI117342.PubMedCentralCrossRefPubMed
24.
go back to reference Sugiyama S, Okada Y, Sukhova G, Virmani R, Heinecke JW, Libby P: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. The American Journal of Pathology. 2001, 158: 879-891.PubMedCentralCrossRefPubMed Sugiyama S, Okada Y, Sukhova G, Virmani R, Heinecke JW, Libby P: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. The American Journal of Pathology. 2001, 158: 879-891.PubMedCentralCrossRefPubMed
25.
go back to reference Thukkani AK, McHowat J, Hsu FF, Brennan ML, Hazen SL, DA F: Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation. 2003, 108: 3128-3133. 10.1161/01.CIR.0000104564.01539.6A.CrossRefPubMed Thukkani AK, McHowat J, Hsu FF, Brennan ML, Hazen SL, DA F: Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation. 2003, 108: 3128-3133. 10.1161/01.CIR.0000104564.01539.6A.CrossRefPubMed
26.
go back to reference Hazell L, Baernthaler G, Stocker R: Correlation between intima-to-media ratio, apolipoprotein B-100, myeloperoxidase, and hypochlorite-oxidized proteins in human atherosclerosis. Free Radical Biology & Medicine. 2001, 31: 1254-1262.CrossRef Hazell L, Baernthaler G, Stocker R: Correlation between intima-to-media ratio, apolipoprotein B-100, myeloperoxidase, and hypochlorite-oxidized proteins in human atherosclerosis. Free Radical Biology & Medicine. 2001, 31: 1254-1262.CrossRef
27.
go back to reference Askari AT, ML B, Zhou X, Drinko J, Thomas J, Topol E, Hazen S, Penn M: Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. Journal of Experimental Medicine. 2003, 197 (5): 615-10.1084/jem.20021426.PubMedCentralCrossRefPubMed Askari AT, ML B, Zhou X, Drinko J, Thomas J, Topol E, Hazen S, Penn M: Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. Journal of Experimental Medicine. 2003, 197 (5): 615-10.1084/jem.20021426.PubMedCentralCrossRefPubMed
28.
go back to reference Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001, 286: 2136-2142. 10.1001/jama.286.17.2136.CrossRefPubMed Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001, 286: 2136-2142. 10.1001/jama.286.17.2136.CrossRefPubMed
29.
go back to reference Brennan M, Penn M, Van Lente F, Nambi V, Shishehbor M, Aviles RJ, Goormastic M, Pepoy M, McErlean E, Topol E, et al: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003, 349: 1595-1604. 10.1056/NEJMoa035003.CrossRefPubMed Brennan M, Penn M, Van Lente F, Nambi V, Shishehbor M, Aviles RJ, Goormastic M, Pepoy M, McErlean E, Topol E, et al: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003, 349: 1595-1604. 10.1056/NEJMoa035003.CrossRefPubMed
30.
go back to reference Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CQ, CAPTURE Investigators: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003, 108: 1440-1445. 10.1161/01.CIR.0000090690.67322.51.CrossRefPubMed Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CQ, CAPTURE Investigators: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003, 108: 1440-1445. 10.1161/01.CIR.0000090690.67322.51.CrossRefPubMed
31.
go back to reference Meuwese M, Stroes E, Hazen S, van Miert J, Kuivenhoven J, Schaub R, Wareham N, Luben R, Kastelein J, Khaw K, et al: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: The EPIC-Norfolk prospective population study. Journal of the American College of Cardiology. 2007, 50 (2): 159-165. 10.1016/j.jacc.2007.03.033.CrossRefPubMed Meuwese M, Stroes E, Hazen S, van Miert J, Kuivenhoven J, Schaub R, Wareham N, Luben R, Kastelein J, Khaw K, et al: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: The EPIC-Norfolk prospective population study. Journal of the American College of Cardiology. 2007, 50 (2): 159-165. 10.1016/j.jacc.2007.03.033.CrossRefPubMed
32.
go back to reference Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A: Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematologica. 2000, 104: 10-15. 10.1159/000041062.CrossRefPubMed Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A: Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematologica. 2000, 104: 10-15. 10.1159/000041062.CrossRefPubMed
33.
go back to reference Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio R: Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. The American Journal of Medicine. 2004, 116: 429-430. 10.1016/j.amjmed.2003.10.025.CrossRefPubMed Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio R: Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. The American Journal of Medicine. 2004, 116: 429-430. 10.1016/j.amjmed.2003.10.025.CrossRefPubMed
34.
go back to reference Asselbergs FW, Tervaert JW, Tio RA: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2004, 350: 516-518. 10.1056/NEJM200401293500519.CrossRefPubMed Asselbergs FW, Tervaert JW, Tio RA: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2004, 350: 516-518. 10.1056/NEJM200401293500519.CrossRefPubMed
35.
go back to reference Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA: A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001, 142: 336-339. 10.1067/mhj.2001.116769.CrossRefPubMed Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA: A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001, 142: 336-339. 10.1067/mhj.2001.116769.CrossRefPubMed
36.
go back to reference Semenkovich C: Fatty acid metabolism and vascular disease. Trends in Cardiovascular Medicine. 2004, 14: 72-76. 10.1016/j.tcm.2003.12.004.CrossRefPubMed Semenkovich C: Fatty acid metabolism and vascular disease. Trends in Cardiovascular Medicine. 2004, 14: 72-76. 10.1016/j.tcm.2003.12.004.CrossRefPubMed
37.
go back to reference Steinberg H, Baron AD: Vascular function, insulin resistance and fatty acids. Diabetologia. 2002, 45: 623-634. 10.1007/s00125-002-0800-2.CrossRefPubMed Steinberg H, Baron AD: Vascular function, insulin resistance and fatty acids. Diabetologia. 2002, 45: 623-634. 10.1007/s00125-002-0800-2.CrossRefPubMed
38.
go back to reference Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P: Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003, 52: 2882-2887. 10.2337/diabetes.52.12.2882.CrossRefPubMed Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P: Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003, 52: 2882-2887. 10.2337/diabetes.52.12.2882.CrossRefPubMed
39.
go back to reference Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999, 48 (9): 1856-10.2337/diabetes.48.9.1856.CrossRefPubMed Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999, 48 (9): 1856-10.2337/diabetes.48.9.1856.CrossRefPubMed
40.
go back to reference Cusi K, Conmstock J, Cunningham G: Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care. 1995, 18: 843-851. 10.2337/diacare.18.6.843.CrossRefPubMed Cusi K, Conmstock J, Cunningham G: Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care. 1995, 18: 843-851. 10.2337/diacare.18.6.843.CrossRefPubMed
41.
go back to reference Kashyap S, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, et al: Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab. 2004, 287: E537-546. 10.1152/ajpendo.00541.2003.CrossRefPubMed Kashyap S, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, et al: Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab. 2004, 287: E537-546. 10.1152/ajpendo.00541.2003.CrossRefPubMed
42.
go back to reference Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berrial Rachele, Bajaj M, Mandarino L, DeFronzo R, Cusi K: A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003, 52 (10): 2461-10.2337/diabetes.52.10.2461.CrossRefPubMed Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berrial Rachele, Bajaj M, Mandarino L, DeFronzo R, Cusi K: A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003, 52 (10): 2461-10.2337/diabetes.52.10.2461.CrossRefPubMed
43.
go back to reference Roldan V: Soluble E-Selectin in cardiovascular disease and its risk factors: A review of the literature. Thrombosis and Haemostasis. 2003, 90: 1007.PubMed Roldan V: Soluble E-Selectin in cardiovascular disease and its risk factors: A review of the literature. Thrombosis and Haemostasis. 2003, 90: 1007.PubMed
44.
go back to reference Guray U, Erbay R, Güray Y, Yilmaz MB, Boyacý AA, Sasmaz H, Korkmaz S, Kütük E: Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. International Journal of Cardiology. 2004, 96 (2): 235-10.1016/j.ijcard.2003.07.014.CrossRefPubMed Guray U, Erbay R, Güray Y, Yilmaz MB, Boyacý AA, Sasmaz H, Korkmaz S, Kütük E: Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. International Journal of Cardiology. 2004, 96 (2): 235-10.1016/j.ijcard.2003.07.014.CrossRefPubMed
45.
go back to reference Pontiroli AE: Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. European Journal of Endocrinology. 2004, 150 (2): 195-10.1530/eje.0.1500195.CrossRefPubMed Pontiroli AE: Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. European Journal of Endocrinology. 2004, 150 (2): 195-10.1530/eje.0.1500195.CrossRefPubMed
46.
go back to reference Hak AE, Pols H, Stehouwer C, Meijer J, Kiliaan AJ, Hofman A, Breteler MB, Witteman J: Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. Journal of Clinical Endocrinology & Metabolism. 2001, 86 (9): 4398.CrossRef Hak AE, Pols H, Stehouwer C, Meijer J, Kiliaan AJ, Hofman A, Breteler MB, Witteman J: Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. Journal of Clinical Endocrinology & Metabolism. 2001, 86 (9): 4398.CrossRef
47.
go back to reference Couillard C, Ruel G, Archer W, Pomerleau S, Bergeron J, Couture P, Lamarche B, Bergeron N: Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. Journal of Clinical Endocrinology & Metabolism. 2005, 90: 6454.CrossRef Couillard C, Ruel G, Archer W, Pomerleau S, Bergeron J, Couture P, Lamarche B, Bergeron N: Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. Journal of Clinical Endocrinology & Metabolism. 2005, 90: 6454.CrossRef
48.
go back to reference Musial K, Polak-Jonkisz D, Berny U, Szprynger K, Szczepanska M: Serum VCAM-1, ICAM-1, and L-selectin levels in children and young adults with chronic renal failure. Pediatric Nephrology. 2005, 20: 52-10.1007/s00467-004-1691-x.CrossRefPubMed Musial K, Polak-Jonkisz D, Berny U, Szprynger K, Szczepanska M: Serum VCAM-1, ICAM-1, and L-selectin levels in children and young adults with chronic renal failure. Pediatric Nephrology. 2005, 20: 52-10.1007/s00467-004-1691-x.CrossRefPubMed
49.
go back to reference Bannan S, Mansfield MW, Grant PJ: Soluble vascular cell adhesion molecule-1 and E-selectin levels in relation to vascular risk factors and to E-selectin genotype in the first degree relatives of NIDDM patients and in NIDDM patients. Diabetologia. 1998, 41: 460-466. 10.1007/s001250050930.CrossRefPubMed Bannan S, Mansfield MW, Grant PJ: Soluble vascular cell adhesion molecule-1 and E-selectin levels in relation to vascular risk factors and to E-selectin genotype in the first degree relatives of NIDDM patients and in NIDDM patients. Diabetologia. 1998, 41: 460-466. 10.1007/s001250050930.CrossRefPubMed
50.
go back to reference Szmitko PE, Wang C-H, Weisel RD, de Almeida JR, Anderson TJ, Verma S: New Markers of Inflammation and Endothelial Cell Activation: Part I. Circulation. 2003, 108 (16): 1917-1923. 10.1161/01.CIR.0000089190.95415.9F.CrossRefPubMed Szmitko PE, Wang C-H, Weisel RD, de Almeida JR, Anderson TJ, Verma S: New Markers of Inflammation and Endothelial Cell Activation: Part I. Circulation. 2003, 108 (16): 1917-1923. 10.1161/01.CIR.0000089190.95415.9F.CrossRefPubMed
51.
go back to reference Meigs J, Hu F, Rifai N, Manson J: Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004, 291 (16): 1978-1986. 10.1001/jama.291.16.1978.CrossRefPubMed Meigs J, Hu F, Rifai N, Manson J: Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004, 291 (16): 1978-1986. 10.1001/jama.291.16.1978.CrossRefPubMed
52.
go back to reference Cusi K: Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus. Current Diabetes Reports. 2009, 9: 200-207. 10.1007/s11892-009-0033-6.CrossRefPubMed Cusi K: Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus. Current Diabetes Reports. 2009, 9: 200-207. 10.1007/s11892-009-0033-6.CrossRefPubMed
53.
go back to reference Stephan B, Jason PE, Alireza M, Laura C, Mario F, Phillip C, Wenxin M, Albert T, Roger W, Daniel B, et al: Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. The Journal of Clinical Investigation. 2001, 108 (12): 1759-1770.CrossRef Stephan B, Jason PE, Alireza M, Laura C, Mario F, Phillip C, Wenxin M, Albert T, Roger W, Daniel B, et al: Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. The Journal of Clinical Investigation. 2001, 108 (12): 1759-1770.CrossRef
54.
go back to reference Zhang R, Marie-Luise B, Zhongzhou S, Jennifer CM, Dave S, Cheryl EM: Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. The Journal of Biological Chemistry. 2002, 277: 46116-46122. 10.1074/jbc.M209124200.CrossRefPubMed Zhang R, Marie-Luise B, Zhongzhou S, Jennifer CM, Dave S, Cheryl EM: Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. The Journal of Biological Chemistry. 2002, 277: 46116-46122. 10.1074/jbc.M209124200.CrossRefPubMed
55.
go back to reference Zheng L, Nukuna B, Brennan M, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox P, et al: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. The Journal of Clinical Investigation. 2004, 114 (4): 529-541.PubMedCentralCrossRefPubMed Zheng L, Nukuna B, Brennan M, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox P, et al: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. The Journal of Clinical Investigation. 2004, 114 (4): 529-541.PubMedCentralCrossRefPubMed
56.
go back to reference Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JFJ, Hazen SL: Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004, 110: 1134-1139. 10.1161/01.CIR.0000140262.20831.8F.PubMedCentralCrossRefPubMed Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JFJ, Hazen SL: Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004, 110: 1134-1139. 10.1161/01.CIR.0000140262.20831.8F.PubMedCentralCrossRefPubMed
57.
go back to reference Kim F, Tysseling K, Rice J, Pham M, Haji L, Gallis B, Baas A, Paramsothy P, Giachelli C, Corson M, et al: Free fatty acid impairment of nitric oxide production in endothelial cells Is mediated by IKK{beta}. Arterioscler Thromb Vasc Biol. 2005, 25 (5): 989-994. 10.1161/01.ATV.0000160549.60980.a8.CrossRefPubMed Kim F, Tysseling K, Rice J, Pham M, Haji L, Gallis B, Baas A, Paramsothy P, Giachelli C, Corson M, et al: Free fatty acid impairment of nitric oxide production in endothelial cells Is mediated by IKK{beta}. Arterioscler Thromb Vasc Biol. 2005, 25 (5): 989-994. 10.1161/01.ATV.0000160549.60980.a8.CrossRefPubMed
58.
go back to reference Zhang W, Schwartz E, Wang Y, Attrep J, Li Z, Reaven P: Elevated concentrations of nonesterified fatty acids increase monocyte expression of CD11b and adhesion to endothelial cells. Arterioscler Thromb Vasc Biol. 2006, 26: 514-519. 10.1161/01.ATV.0000200226.53994.09.CrossRefPubMed Zhang W, Schwartz E, Wang Y, Attrep J, Li Z, Reaven P: Elevated concentrations of nonesterified fatty acids increase monocyte expression of CD11b and adhesion to endothelial cells. Arterioscler Thromb Vasc Biol. 2006, 26: 514-519. 10.1161/01.ATV.0000200226.53994.09.CrossRefPubMed
59.
go back to reference Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari A, Paolisso G, Marfella R, Giugliano D: Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: Role of fat and carbohydrate meals. J Am Coll Cardiol. 2002, 39 (7): 1145-1150. 10.1016/S0735-1097(02)01741-2.CrossRefPubMed Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari A, Paolisso G, Marfella R, Giugliano D: Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: Role of fat and carbohydrate meals. J Am Coll Cardiol. 2002, 39 (7): 1145-1150. 10.1016/S0735-1097(02)01741-2.CrossRefPubMed
60.
go back to reference Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003, 289 (14): 1799-1804. 10.1001/jama.289.14.1799.CrossRefPubMed Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003, 289 (14): 1799-1804. 10.1001/jama.289.14.1799.CrossRefPubMed
61.
go back to reference Yuan M, Konstantopoulos N, Lee J, Hansen L, Li Z, Karin M, Shoelson S: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKB. Science. 2001, 293 (5535): 1673-1677. 10.1126/science.1061620.CrossRefPubMed Yuan M, Konstantopoulos N, Lee J, Hansen L, Li Z, Karin M, Shoelson S: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKB. Science. 2001, 293 (5535): 1673-1677. 10.1126/science.1061620.CrossRefPubMed
62.
go back to reference Belfort R, Harrison SA, Brown K, Darland C, Finch J, Balas B, Gastaldelli A, Tio F, Hardies J, Pulcini J, et al: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New England Journal of Medicine. 2006, 355: 2297-2307. 10.1056/NEJMoa060326.CrossRefPubMed Belfort R, Harrison SA, Brown K, Darland C, Finch J, Balas B, Gastaldelli A, Tio F, Hardies J, Pulcini J, et al: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New England Journal of Medicine. 2006, 355: 2297-2307. 10.1056/NEJMoa060326.CrossRefPubMed
63.
go back to reference Hagenfeldt L, Wahren J, Pernow B, Raf L: Uptake of individual free acids by skeletal muscle and liver in man. J Clin Invest. 2330, 51: 2324-1972. 10.1172/JCI107043.CrossRef Hagenfeldt L, Wahren J, Pernow B, Raf L: Uptake of individual free acids by skeletal muscle and liver in man. J Clin Invest. 2330, 51: 2324-1972. 10.1172/JCI107043.CrossRef
64.
go back to reference Storz P, Doppler H, Wernig A, Pfizenmaier K, Muller G: Cross talk mechanisms in the development of skeletal muscle cells palmitate rather than tumour necrosis factor inhibits insulin-dependent protein kinase B(PKB)/Akt stimulation and glucose uptake. Eur J Biochem. 1999, 266: 17-25. 10.1046/j.1432-1327.1999.00809.x.CrossRefPubMed Storz P, Doppler H, Wernig A, Pfizenmaier K, Muller G: Cross talk mechanisms in the development of skeletal muscle cells palmitate rather than tumour necrosis factor inhibits insulin-dependent protein kinase B(PKB)/Akt stimulation and glucose uptake. Eur J Biochem. 1999, 266: 17-25. 10.1046/j.1432-1327.1999.00809.x.CrossRefPubMed
65.
go back to reference Schmitz-Peiffer C, Craig DL, Biden TJ: Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem. 4210, 274: 24202-2. 10.1074/jbc.274.34.24202.CrossRef Schmitz-Peiffer C, Craig DL, Biden TJ: Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem. 4210, 274: 24202-2. 10.1074/jbc.274.34.24202.CrossRef
66.
go back to reference Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS: Fish oil prevents insulin resistance induced by high-feeding in rats. Science. 1987, 237: 885-888. 10.1126/science.3303333.CrossRefPubMed Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS: Fish oil prevents insulin resistance induced by high-feeding in rats. Science. 1987, 237: 885-888. 10.1126/science.3303333.CrossRefPubMed
Metadata
Title
Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects
Authors
Manoj Mathew
Eric Tay
Kenneth Cusi
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-9

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.